Diplomat Pharmacy Stock Price, News & Analysis (NYSE:DPLO)

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) released its earnings results on Friday, August, 9th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.01. The business earned $1.29 billion during the quarter, compared to analysts' expectations of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The company's revenue for the quarter was down 9.1% compared to the same quarter last year. During the same period last year, the business earned ($0.05) earnings per share. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy issued an update on its FY19 earnings guidance on Friday, August, 9th. The company provided EPS guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

14 Wall Street analysts have issued 12-month target prices for Diplomat Pharmacy's stock. Their predictions range from $4.00 to $30.00. On average, they anticipate Diplomat Pharmacy's stock price to reach $9.65 in the next twelve months. This suggests a possible upside of 89.5% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Headlines about DPLO stock have trended somewhat negative recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diplomat Pharmacy earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Diplomat Pharmacy.

Diplomat Pharmacy saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 7,680,000 shares, a decline of 7.6% from the August 15th total of 8,310,000 shares. Based on an average daily trading volume, of 790,800 shares, the days-to-cover ratio is currently 9.7 days. Currently, 13.3% of the shares of the company are sold short. View Diplomat Pharmacy's Current Options Chain.

Some companies that are related to Diplomat Pharmacy include Covetrus (CVET), Rite Aid (RAD), 111 (YI), Petmed Express (PETS), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), CVS Health (CVS), Cannabis Sativa (CBDS), Horizon Therapeutics (HZNP), Servicesource International (SREV), Ford Motor (F), Activision Blizzard (ATVI) and Cara Therapeutics (CARA).

Diplomat Pharmacy's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.40%) and State of Alaska Department of Revenue (0.06%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Regina M Benjamin. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $5.10.

Diplomat Pharmacy has a market capitalization of $386.35 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]